应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02552 华领医药-B
休市中 11-22 16:08:13
1.320
-0.240
-15.38%
最高
1.460
最低
1.200
成交量
2,022万
今开
1.400
昨收
1.560
日振幅
16.67%
总市值
13.93亿
流通市值
13.93亿
总股本
10.56亿
成交额
2,701万
换手率
1.92%
流通股本
10.56亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
超40亿元里程碑付款还没收到一半，华领医药和拜耳分手了
第一财经 · 11-22 22:46
超40亿元里程碑付款还没收到一半，华领医药和拜耳分手了
与华领医药半道分手 拜耳“血亏”超10亿
经济观察报 · 11-22 21:28
与华领医药半道分手 拜耳“血亏”超10亿
华领医药与拜耳“分手”，收回糖尿病药物商业化权益，已获里程碑付款15亿元
时代财经 · 11-22 20:07
华领医药与拜耳“分手”，收回糖尿病药物商业化权益，已获里程碑付款15亿元
华领医药-B11月22日遭主力抛售285万元 环比增加427.78%
市场透视 · 11-22 16:16
华领医药-B11月22日遭主力抛售285万元 环比增加427.78%
华领医药独苗产品结束与拜耳合作，谁会接盘？
界面 · 11-22 15:32
华领医药独苗产品结束与拜耳合作，谁会接盘？
华领医药-B(02552)：自2025年1月1日起终止拜耳华堂宁®代理销售权
智通财经 · 11-22 10:05
华领医药-B(02552)：自2025年1月1日起终止拜耳华堂宁®代理销售权
《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作
路透中文 · 11-22 09:48
《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作
华领医药将接管华堂宁商业化责任，终止与拜耳协议
财中社 · 11-22 09:45
华领医药将接管华堂宁商业化责任，终止与拜耳协议
华领医药-B(02552)下跌9.62%，报1.41元/股
金融界 · 11-22 09:44
华领医药-B(02552)下跌9.62%，报1.41元/股
华领医药-B盘中异动 早盘急速下挫19.87%
市场透视 · 11-22 09:35
华领医药-B盘中异动 早盘急速下挫19.87%
华领医药(02552)向拜耳医药收回华堂宁®中国商业化权
金吾财讯 · 11-22 08:58
华领医药(02552)向拜耳医药收回华堂宁®中国商业化权
华领医药(02552.HK)附属有意自明年起将华堂宁中国商业化责任过渡
阿斯达克财经 · 11-22 08:46
华领医药(02552.HK)附属有意自明年起将华堂宁中国商业化责任过渡
华领医药-B宣布华堂宁®商业化过渡，开启新市场战略
格隆汇 · 11-22 07:40
华领医药-B宣布华堂宁®商业化过渡，开启新市场战略
华领医药-B(02552)上涨5.88%，报1.62元/股
金融界 · 11-20 13:04
华领医药-B(02552)上涨5.88%，报1.62元/股
华领医药-B盘中异动 早盘股价大涨5.23%报1.610港元
市场透视 · 11-20 09:43
华领医药-B盘中异动 早盘股价大涨5.23%报1.610港元
华领医药-B(02552)下跌6.13%，报1.53元/股
金融界 · 11-19
华领医药-B(02552)下跌6.13%，报1.53元/股
华领医药-B盘中异动 临近午盘股价大跌5.52%报1.540港元
市场透视 · 11-19
华领医药-B盘中异动 临近午盘股价大跌5.52%报1.540港元
华领医药－Ｂ(02552)股价下跌5.521%，现价港币$1.54
阿斯达克财经 · 11-19
华领医药－Ｂ(02552)股价下跌5.521%，现价港币$1.54
华领医药-B盘中异动 急速下挫5.99%报1.570港元
市场透视 · 11-15
华领医药-B盘中异动 急速下挫5.99%报1.570港元
华领医药-B(02552)下跌5.85%，报1.61元/股
金融界 · 11-14
华领医药-B(02552)下跌5.85%，报1.61元/股
加载更多
公司概况
公司名称：
华领医药-B
所属市场：
SEHK
上市日期：
--
主营业务：
华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力於开发用於治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。该公司主要在国内外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"02552","market":"HK","secType":"STK","nameCN":"华领医药-B","latestPrice":1.32,"timestamp":1732262893015,"preClose":1.56,"halted":0,"volume":20216500,"delay":0,"floatShares":1055588761,"shares":1055588761,"eps":-0.23184043,"marketStatus":"休市中","marketStatusCode":7,"change":-0.24,"latestTime":"11-22 16:08:13","open":1.4,"high":1.46,"low":1.2,"amount":27006835,"amplitude":0.166667,"askPrice":1.38,"askSize":8000,"bidPrice":1.32,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.2880927806883023,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1536854400000,"adjPreClose":1.56,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":11.469910780413612,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02552","defaultTab":"news","newsList":[{"id":"2485526485","title":"超40亿元里程碑付款还没收到一半，华领医药和拜耳分手了","url":"https://stock-news.laohu8.com/highlight/detail?id=2485526485","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485526485?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:46","pubTimestamp":1732286760,"startTime":"0","endTime":"0","summary":"华堂宁是华领医药唯一商业化的产品，在被纳入国家医保药品目录后，华领医药股价和毛利率均大受拖累。根据协议条款，华领医药可获得额外最高可达41.8亿元的销售里程碑付款。自与拜耳合作以来，华堂宁已达成数个相关的里程碑，华领医药也因此获得丰厚的回报。华领医药称，随着多格列艾汀的生产规模扩大，公司预计毛利率将会上升。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-22/doc-incwycqa3764056.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-22/doc-incwycqa3764056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2485044268","title":"与华领医药半道分手 拜耳“血亏”超10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2485044268","media":"经济观察报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485044268?lang=zh_cn&edition=full","pubTime":"2024-11-22 21:28","pubTimestamp":1732282106,"startTime":"0","endTime":"0","summary":"经济观察网 记者 张铃 11月22日，华领医药（02552.HK）发布公告，已于11月21日向拜耳发出书面通知，自2025年1月1日起，将收回其开发的糖尿病药品华堂宁在中国的商业化权益。在外界看来，华领医药与拜耳这一合作终止得很突然。就在两周前的进博会上，拜耳集团处方药事业部副总裁、中国医学部负责人李瑶在接受媒体采访时，还...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OVoOnwSPrwujzgrnOfyveEGg1TXsHQ-XVC_bJsvUYwL5kAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OVoOnwSPrwujzgrnOfyveEGg1TXsHQ-XVC_bJsvUYwL5kAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241122A09ILT00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241122A09ILT00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2485251701","title":"华领医药与拜耳“分手”，收回糖尿病药物商业化权益，已获里程碑付款15亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485251701","media":"时代财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485251701?lang=zh_cn&edition=full","pubTime":"2024-11-22 20:07","pubTimestamp":1732277229,"startTime":"0","endTime":"0","summary":"本文来源：时代财经 作者：李傲华11月22日，华领医药-B（02552.HK）发布公告称，其全资附属公司华领医药技术（上海）有限公司向拜耳医药保健有限公司（下称“拜耳”）发出书面通知，表示有意自2025年1月1日起，将用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（多格列艾汀片，dorzagliatin）在中国的商业化责任过渡至华领...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OkZRfC7iHWXV1IqnhMbRdjH85S5bw_Jx9PhB3lHQX5cUEAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OkZRfC7iHWXV1IqnhMbRdjH85S5bw_Jx9PhB3lHQX5cUEAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241122A08YQW00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241122A08YQW00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2485523380","title":"华领医药-B11月22日遭主力抛售285万元 环比增加427.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485523380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485523380?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:16","pubTimestamp":1732263364,"startTime":"0","endTime":"0","summary":"11月22日, 华领医药-B股价跌15.38%，报收1.32元，成交金额2700万元，换手率1.92%，振幅16.67%，量比11.44。华领医药-B今日主力资金净流出285万元，连续3日净流出，上一交易日主力净流出54万元，今日环比增加427.78%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为1.97%。该股近5个交易日下跌17.50%，主力资金累计净流出391万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出237万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161639a24d6548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161639a24d6548&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2485827902","title":"华领医药独苗产品结束与拜耳合作，谁会接盘？","url":"https://stock-news.laohu8.com/highlight/detail?id=2485827902","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485827902?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:32","pubTimestamp":1732260742,"startTime":"0","endTime":"0","summary":"自本公告日期起至终止生效日期止，拜耳与华领医药将继续履行现有协议直至终止。另外，华领医药还可能寻求其他潜在合作伙伴继续多格列艾汀的商业化。二者合作期间，华领医药收到拜耳的里程碑款项合计已达到15亿元。而截止发稿，华领医药未就此事作出回应。华领医药在2024年中报中表示，其目标是2025年实现盈利。华领医药表示，其专注于FDC新候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122153402a24d4b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122153402a24d4b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2485245477","title":"华领医药-B(02552)：自2025年1月1日起终止拜耳华堂宁®代理销售权","url":"https://stock-news.laohu8.com/highlight/detail?id=2485245477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485245477?lang=zh_cn&edition=full","pubTime":"2024-11-22 10:05","pubTimestamp":1732241110,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月22日，华领医药-B公布，公司向拜耳医药保健有限公司发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至公司。为实现过渡，公司有权并计划自2025年1月1日起终止协议。据了解，华领医药与拜耳于2020年8月17日签署关于华堂宁 的战略合作协议。截至目前，华领医药收到拜耳的里程碑款项合共已达到15亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02552","BK1574","BK1191"],"gpt_icon":0},{"id":"2485472677","title":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485472677","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485472677?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:48","pubTimestamp":1732240139,"startTime":"0","endTime":"0","summary":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至该公司。为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT03R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2485477832","title":"华领医药将接管华堂宁商业化责任，终止与拜耳协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2485477832","media":"财中社","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485477832?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:45","pubTimestamp":1732239951,"startTime":"0","endTime":"0","summary":"财中社11月22日电华领医药-B（02552）发布公告，宣布其全资附属公司华领医药技术（上海）有限公司计划自2025年1月1日起，将其开发的用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁?的商业化责任过渡至公司。该决策源于与拜耳医药保健有限公司于2020年8月17日建立的合作关系，该合作赋予拜耳在中国的独家商业化权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411223247629313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2485761472","title":"华领医药-B(02552)下跌9.62%，报1.41元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485761472","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485761472?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:44","pubTimestamp":1732239873,"startTime":"0","endTime":"0","summary":"11月22日，华领医药-B(02552)盘中下跌9.62%，截至09:44，报1.41元/股，成交1028.74万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/22094445559614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02552","BK1191","BK1574"],"gpt_icon":0},{"id":"2485472201","title":"华领医药-B盘中异动 早盘急速下挫19.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485472201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485472201?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:35","pubTimestamp":1732239315,"startTime":"0","endTime":"0","summary":"2024年11月22日早盘09时35分，华领医药-B股票出现波动，股价快速跳水19.87%。截至发稿，该股报1.250港元/股，成交量499.75万股，换手率0.47%，振幅13.46%。华领医药-B股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，晶泰科技、来凯医药-B、宜明昂科-B涨幅较大，振幅较大的相关个股有华领医药-B、晶泰科技、来凯医药-B，振幅分别为13.46%、5.45%、4.21%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112209351698e44070&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112209351698e44070&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2485791844","title":"华领医药(02552)向拜耳医药收回华堂宁®中国商业化权","url":"https://stock-news.laohu8.com/highlight/detail?id=2485791844","media":"金吾财讯","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485791844?lang=zh_cn&edition=full","pubTime":"2024-11-22 08:58","pubTimestamp":1732237086,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华领医药 公告，于2024年11月21日，其全资附属公司华领上海向拜耳医药保健有限公司发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至公司。于2020年8月17日，有关各方就华堂宁在中国的商业化建立合作关系并订立相关的独家推广服务协议。根据协议，拜耳获得华堂宁于中国的独家商业化权。自拜耳合作以来，已达成数个与华堂宁相关的里程碑。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552","09939","159938","BK1515","BK1191","BK1161","BK1574"],"gpt_icon":0},{"id":"2485847922","title":"华领医药(02552.HK)附属有意自明年起将华堂宁中国商业化责任过渡","url":"https://stock-news.laohu8.com/highlight/detail?id=2485847922","media":"阿斯达克财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485847922?lang=zh_cn&edition=full","pubTime":"2024-11-22 08:46","pubTimestamp":1732236360,"startTime":"0","endTime":"0","summary":"华领医药公布，其全资附属华领上海向拜耳发出书面通知，表示有意自明年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至公司。于2020年8月17日，有关各方就华堂宁在中国的商业化建立合作关系并订立相关的独家推广服务协议，拜耳获得华堂宁于中国的独家商业化权。自目前起至终止生效日期止，拜耳与公司将继续履行协议项下的义务并承诺启动一个友好的、以患者为中心的过渡计划。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190801114232246_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190801114232246_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398677/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2485478164","title":"华领医药-B宣布华堂宁®商业化过渡，开启新市场战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2485478164","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485478164?lang=zh_cn&edition=full","pubTime":"2024-11-22 07:40","pubTimestamp":1732232433,"startTime":"0","endTime":"0","summary":"格隆汇11月22日丨华领医药-B发布公告，2024年11月21日，其全资附属公司华领医药技术(上海)有限公司向拜耳医药保健有限公司发出书面通知，表示有意自2025年1月1日起，将公司开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至公司。根据协议，拜耳获得华堂宁于中国的独家商业化权。为支持华堂宁在中国的持续商业销售，公司可能会寻求其他潜在合作伙伴，以在中国进行华堂宁的商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122074033a24c5b95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122074033a24c5b95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2484158499","title":"华领医药-B(02552)上涨5.88%，报1.62元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484158499","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484158499?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:04","pubTimestamp":1732079092,"startTime":"0","endTime":"0","summary":"11月20日，华领医药-B(02552)盘中上涨5.88%，截至13:04，报1.62元/股，成交118.49万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20130445477841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2484187000","title":"华领医药-B盘中异动 早盘股价大涨5.23%报1.610港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484187000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484187000?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:43","pubTimestamp":1732067039,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘09时43分，华领医药-B股票出现波动，股价快速上涨5.23%。截至发稿，该股报1.610港元/股，成交量35.05万股，换手率0.03%，振幅7.19%。资金方面，该股资金流入31.108万港元，流出21.6585万港元。华领医药-B股票所在的生物技术行业中，整体跌幅为0.17%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120094359abd0a226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120094359abd0a226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2484952095","title":"华领医药-B(02552)下跌6.13%，报1.53元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484952095","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484952095?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:37","pubTimestamp":1731987437,"startTime":"0","endTime":"0","summary":"11月19日，华领医药-B(02552)盘中下跌6.13%，截至11:37，报1.53元/股，成交107.14万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/19113745438956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2484952596","title":"华领医药-B盘中异动 临近午盘股价大跌5.52%报1.540港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484952596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484952596?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:36","pubTimestamp":1731987380,"startTime":"0","endTime":"0","summary":"2024年11月19日临近午盘11时36分，华领医药-B股票出现异动，股价急速下跌5.52%。截至发稿，该股报1.540港元/股，成交量62.6556万股，换手率0.06%，振幅5.52%。资金方面，该股资金流入3.06万港元，流出91.85万港元。华领医药-B股票所在的生物技术行业中，整体跌幅为0.06%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力于开发用于治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119113620abce1487&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119113620abce1487&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2484957325","title":"华领医药－Ｂ(02552)股价下跌5.521%，现价港币$1.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2484957325","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484957325?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:36","pubTimestamp":1731987360,"startTime":"0","endTime":"0","summary":"[下跌股]华领医药－Ｂ(02552) 股价在上午11:36比前收市价下跌5.521%，现股价为港币$1.54。至目前为止，今日最高价为$1.63，而最低价为$1.54。总成交量为62.656万股，总成交金额为港币$99.399万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD241119612/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02552","BK1574"],"gpt_icon":0},{"id":"2483636469","title":"华领医药-B盘中异动 急速下挫5.99%报1.570港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483636469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483636469?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:35","pubTimestamp":1731634552,"startTime":"0","endTime":"0","summary":"2024年11月15日早盘09时35分，华领医药-B股票出现波动，股价急速下挫5.99%。截至发稿，该股报1.570港元/股，成交量1.75万股，换手率0.00%，振幅2.40%。资金方面，该股资金流入0港元，流出1.282万港元。华领医药-B股票所在的生物技术行业中，整体涨幅为0.09%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力于开发用于治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111509355298e42c61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111509355298e42c61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2483848724","title":"华领医药-B(02552)下跌5.85%，报1.61元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848724","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483848724?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:14","pubTimestamp":1731568443,"startTime":"0","endTime":"0","summary":"11月14日，华领医药-B(02552)盘中下跌5.85%，截至15:14，报1.61元/股，成交103.15万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司，其核心产品华堂宁，也即多格列艾汀片，已于2022年9月30日获得中国国家药品监督管理局的上市批准，主要用于治疗2型糖尿病。华领医药的未来发展断点涵盖新产品上市、新市场开拓和新疾病领域三个维度，期望在全球范围内推动医药创新。截至2024年中报，华领医药-B营业总收入1.03亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14151445285345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02552","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huamedicine.com","stockEarnings":[{"period":"1week","weight":-0.175},{"period":"1month","weight":-0.1646},{"period":"3month","weight":0.1478},{"period":"6month","weight":-0.1538},{"period":"1year","weight":-0.3125},{"period":"ytd","weight":-0.3299}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力於开发用於治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。该公司主要在国内外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.009978},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.055195},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104259},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.047122},{"month":5,"riseRate":0.5,"avgChangeRate":0.063673},{"month":6,"riseRate":0.5,"avgChangeRate":0.0552},{"month":7,"riseRate":0.333333,"avgChangeRate":0.009836},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059642},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.002881},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.089836},{"month":11,"riseRate":0.571429,"avgChangeRate":0.080024},{"month":12,"riseRate":0.666667,"avgChangeRate":0.051948}],"exchange":"SEHK","name":"华领医药-B","nameEN":"HUA MEDICINE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华领医药-B,02552,华领医药-B股票,华领医药-B股票老虎,华领医药-B股票老虎国际,华领医药-B行情,华领医药-B股票行情,华领医药-B股价,华领医药-B股市,华领医药-B股票价格,华领医药-B股票交易,华领医药-B股票购买,华领医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}